Were Christine Mikail Cvijic’s Neurogene (NGNE) share sales pre-planned?

Yes. A footnote explains that all transactions were executed under a Rule 10b5-1 trading plan adopted on August 18, 2025. Such plans allow insiders to schedule trades in advance, helping separate trading timing from day-to-day business decisions.

Neurogene (NGNE) CFO’s 4,800-share sale under 10b5-1 plan

Q: What did Neurogene (NGNE) executive Christine Mikail Cvijic report in this Form 4?

Cvijic reported selling 4,800 shares of Neurogene common stock in open-market transactions. The sales were split across three trades on July 1–2, 2026 at prices around $34–$35 per share , under a pre-arranged Rule 10b5-1 trading plan.

Q: At what prices did Christine Mikail Cvijic sell Neurogene (NGNE) shares?

The reported weighted average sale prices were $34.059 , $34.579 , and $35.227 per share. Footnotes state each sale involved multiple trades within narrow ranges around those prices, and detailed price breakdowns are available upon request from the company or the SEC.

Q: How many Neurogene (NGNE) shares does Christine Mikail Cvijic hold after these sales?

After the reported transactions, Cvijic directly owns 88,840 shares of Neurogene common stock. Footnotes also describe additional unvested restricted stock units that are scheduled to vest in several installments between 2027 and 2029 , supplementing her equity position.

Q: How many Neurogene (NGNE) restricted stock units are reported for Christine Mikail Cvijic?

The filing states she holds unvested awards of 10,635 RSUs , 13,533 RSUs , and 22,000 RSUs . These units are scheduled to vest on specific dates between March 2027 and February 2029 , subject to continued service or plan terms.

Filing Impact

(High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Neurogene Inc. director and President/CFO Christine Mikail Cvijic reported open-market sales of 4,800 shares of common stock. The sales occurred on July 1–2, 2026 in three tranches at weighted average prices around $34–$35 per share.

The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 18, 2025, and involved shares held jointly with her spouse. Following these sales, she continues to directly hold 88,840 shares, along with additional unvested restricted stock units scheduled to vest between 2027 and 2029.

Insider Trade Summary 10b5-1

Net Seller: 4,800 shares ($166,586)

Net Sell 3 txns

Insider Cvijic Christine Mikail

Role President and CFO

Sold 4,800 shs ($167K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,531	$34.579	$88K
Sale	Common Stock	1,530	$35.227	$54K
Sale	Common Stock	739	$34.059	$25K

Holdings After Transaction: Common Stock — 90,370 shares (Direct, null)

Footnotes (1)

The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.005 to $34.095, inclusive. The reporting person undertakes to provide Neurogene Inc. (the "Company"), any securityholder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, following completion of all sales reported pursuant to this Form 4, 4,800 are held jointly by the reporting person and her spouse, David Cvijic. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.05 to $34.99, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.11 to $35.255, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote

Key Figures

Shares sold: 4,800 shares Sale prices: $34.059, $34.579, $35.227 per share Shares held after: 88,840 shares +4 more

7 metrics

Shares sold 4,800 shares Total common shares sold July 1–2, 2026

Sale prices $34.059, $34.579, $35.227 per share Weighted average prices for three sale tranches

Shares held after 88,840 shares Direct common stock ownership following reported sales

RSU grant 1 10,635 RSUs Granted March 13, 2024; vests March 13, 2027

RSU grant 2 13,533 RSUs Granted March 26, 2025; vests in 2027 and 2028

RSU grant 3 22,000 RSUs Granted February 20, 2026; vests 2027–2029

Jointly held shares 4,800 shares Shares held jointly with spouse after reported sales

Key Terms

Rule 10b5-1 plan, restricted stock units, weighted average price, open-market sale

4 terms

Rule 10b5-1 plan financial

"The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025."

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

restricted stock units financial

"Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027..."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average price financial

"The price reported is a weighted average price. These shares were sold in multiple transactions..."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action: "open-market sale"; transaction_code_description: "Sale in open market or private transaction""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/02/2026 - 06:43 PM Accepted by SEC EDGAR 07/02/2026 - 06:42 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cvijic Christine Mikail

(Last)

(First)

(Middle)

C/O NEUROGENE INC.

535 W 24TH STREET, 5TH FLOOR

(Street)

NEW YORK

10011

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Neurogene Inc. [ NGNE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President and CFO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	07/01/2026		S⁽¹⁾		739	D	$34.059⁽²⁾	92,901	D⁽³⁾
Common Stock	07/02/2026		S⁽¹⁾		2,531	D	$34.579⁽⁴⁾	90,370	D⁽³⁾
Common Stock	07/02/2026		S⁽¹⁾		1,530	D	$35.227⁽⁵⁾	88,840	D⁽³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic.

2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.005 to $34.095, inclusive. The reporting person undertakes to provide Neurogene Inc. (the "Company"), any securityholder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, following completion of all sales reported pursuant to this Form 4, 4,800 are held jointly by the reporting person and her spouse, David Cvijic.

4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.05 to $34.99, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote

5. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.11 to $35.255, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote

Remarks:

	/s/ Donna M. Cochener as attorney-in-fact for Christine Mikail Cvijic	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Neurogene (NGNE) executive Christine Mikail Cvijic report in this Form 4?

Cvijic reported selling 4,800 shares of Neurogene common stock in open-market transactions. The sales were split across three trades on July 1–2, 2026 at prices around $34–$35 per share, under a pre-arranged Rule 10b5-1 trading plan.

At what prices did Christine Mikail Cvijic sell Neurogene (NGNE) shares?

The reported weighted average sale prices were $34.059, $34.579, and $35.227 per share. Footnotes state each sale involved multiple trades within narrow ranges around those prices, and detailed price breakdowns are available upon request from the company or the SEC.

How many Neurogene (NGNE) shares does Christine Mikail Cvijic hold after these sales?

After the reported transactions, Cvijic directly owns 88,840 shares of Neurogene common stock. Footnotes also describe additional unvested restricted stock units that are scheduled to vest in several installments between 2027 and 2029, supplementing her equity position.

How many Neurogene (NGNE) restricted stock units are reported for Christine Mikail Cvijic?

The filing states she holds unvested awards of 10,635 RSUs, 13,533 RSUs, and 22,000 RSUs. These units are scheduled to vest on specific dates between March 2027 and February 2029, subject to continued service or plan terms.

Were Christine Mikail Cvijic’s sold Neurogene (NGNE) shares held jointly?

Yes. A footnote notes that the shares sold in these transactions were held jointly by Cvijic and her spouse, David Cvijic. It also states that 4,800 shares remain held jointly after completion of all sales reported in this Form 4.